Literature DB >> 11027418

Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder.

T Beer1, D Raghavan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11027418     DOI： 10.1002/1097-0045(20001001)45:2<184::aid-pros13>3.0.co;2-k

Source DB:  PubMed          Journal:  Prostate        ISSN： 0270-4137            Impact factor:   4.104


× No keyword cloud information.
  5 in total

1.  The future in advanced prostate cancer: take your partners or is the last dance for me?

Authors:  David I Quinn
Journal:  Rev Urol       Date:  2004

2.  Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.

Authors:  Randall E Millikan; Sijin Wen; Lance C Pagliaro; Melissa A Brown; Brenda Moomey; Kim-Anh Do; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2008-11-24       Impact factor: 44.544

3.  Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer.

Authors:  Ke Li; Wenhua Zhan; Yulong Chen; Rajiv Kumar Jha; Xueli Chen
Journal:  Front Pharmacol       Date:  2019-12-18       Impact factor: 5.810

4.  Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!

Authors:  D Raghavan
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

Review 5.  Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.

Authors:  Tomasz M Beer; Joseph S Bubalo
Journal:  Curr Urol Rep       Date:  2002-06       Impact factor: 2.862
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.